{"id":"https://openalex.org/A5046420122","orcid":null,"observed_orcids":[],"display_name":"Alexis I. Brinkerhoff","raw_author_names":["Alexis I. Brinkerhoff"],"full_name":"Alexis I. Brinkerhoff","works_count":1,"cited_by_count":0,"summary_stats":{"2yr_mean_citedness":0.0,"h_index":0,"i10_index":0},"ids":{"openalex":"https://openalex.org/A5046420122","orcid":null,"observed_orcids":[]},"affiliations":[{"institution":{"id":"https://openalex.org/I2613432","ror":"https://ror.org/032db5x82","display_name":"University of South Florida","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]},"years":[2016]}],"last_known_institutions":[{"id":"https://openalex.org/I2613432","ror":"https://ror.org/032db5x82","display_name":"University of South Florida","country_code":"US","type":"education","lineage":["https://openalex.org/I2613432"]}],"topics":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","count":1,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","count":1,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","count":1,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"topic_share":[{"id":"https://openalex.org/T11535","display_name":"Chemotherapy-induced cardiotoxicity and mitigation","value":1.96e-05,"subfield":{"id":"https://openalex.org/subfields/2705","display_name":"Cardiology and Cardiovascular Medicine"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T11914","display_name":"PARP inhibition in cancer therapy","value":1.69e-05,"subfield":{"id":"https://openalex.org/subfields/2730","display_name":"Oncology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T12356","display_name":"Bioactive Compounds and Antitumor Agents","value":7.5e-06,"subfield":{"id":"https://openalex.org/subfields/3005","display_name":"Toxicology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"x_concepts":[{"id":"182979987","wikidata":"https://www.wikidata.org/wiki/Q3907241","display_name":"Poly ADP ribose polymerase","score":0.5120590329170227},{"id":"185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","score":0.41865792870521545},{"id":"126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","score":0.2654702663421631},{"id":"181199279","wikidata":"https://www.wikidata.org/wiki/Q8047","display_name":"Enzyme","score":0.2391141951084137},{"id":"104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","score":0.13595718145370483}],"counts_by_year":[{"year":2016,"works_count":1,"oa_works_count":1,"cited_by_count":0}],"display_name_alternatives":["Alexis I. Brinkerhoff"],"block_key":"a brinkerhoff","works_api_url":"https://api.openalex.org/works?filter=author.id:A5046420122","updated_date":"2026-10-05T12:30:24","created_date":"2016-06-24T00:00:00"}